Topical Cream Developed at UMH IDiBE Calms Chemotherapy Side Effects on the Skin
en-GBde-DEes-ESfr-FR

Topical Cream Developed at UMH IDiBE Calms Chemotherapy Side Effects on the Skin


  • Most patients receiving chemotherapy with taxanes or platinum salts develop painful neuropathy in hands and feet, often forcing dose reduction or treatment interruption.
  • Published in Clinical and Translational Oncology, the study demonstrates that topical application of Oncapsisens® delays and reduces neuropathic symptoms, paving the way for new preventive options for cancer patients.
Most patients receiving chemotherapy with taxanes or platinum salts develop pain and loss of sensitivity in their hands and feet—a severe side effect that can interfere with proper treatment. Addressing this unmet clinical need, researchers at the Institute of Research, Development and Innovation in Health Biotechnology of Elche (IDiBE) at Miguel Hernández University (UMH) have coordinated an international clinical trial demonstrating the effectiveness of an innovative topical cream developed at UMH to relieve these symptoms and improve cancer patients’ quality of life.

Up to 80% of patients treated with these types of chemotherapy experience hand–foot neuropathy, an adverse effect that may force dose reduction or even treatment interruption. IDiBE-UMH professors Asia Fernández Carvajal and Antonio Ferrer Montiel coordinated this multicenter clinical trial, which confirms that topical application can significantly reduce the incidence of neuropathy in the hands and delay the onset of symptoms during treatment.
The study, published in the scientific journal Clinical and Translational Oncology, was conducted in nine hospitals across Spain and Belgium, involving 142 cancer patients. The trial compared a conventional moisturizing cream with a nociceutical formulation developed at UMH and marketed by the spin-off company Prospera Biotech.

Results show a reduction in the incidence of hand neuropathy, a delay in the onset of neuropathic symptoms during chemotherapy, and, overall, a lower impact of these symptoms on patients’ daily lives. These findings pave the way for new healthcare options to address an adverse effect that, until now, lacked effective preventive treatments.

“Before the development of this formulation, oncologists and patients had no specific product to relieve these symptoms, which were often so severe that they led to dose reduction or even treatment discontinuation—with consequences for tumor control,” explains UMH Professor Asia Fernández Carvajal. According to the researcher, the rate of dose reduction or treatment abandonment in patients with peripheral neuropathy can reach up to 60%.
For his part, UMH Professor Antonio Ferrer Montiel explains that the ingredients of the cream “protect sensory nerve endings in the skin, which are responsible for discomfort and itching in the peripheral neurosensory system.” In this way, topical protection helps reduce hypersensitivity in hands and feet and improves tolerance to chemotherapy.

The product is currently available in European pharmacies as a neurocosmetic—a safe and, in this case, also effective product that can be used without a prescription. “Moving into clinical trials is not easy, but we believe the effort is worthwhile if it allows this formulation to become an adjuvant during chemotherapy and after treatment, supporting the ongoing care of cancer patients,” concludes Ferrer Montiel.
Servitja, S., Castro-Henriques, M., Álvarez-Busto, I., Díez-Franco, C., Medina-Castillo, A., Algarra-García, M. A., ... & Ferrer-Montiel, A. (2025). A Topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized study. Clinical and Translational Oncology. October 1. https://rdcu.be/eI4oZ
Archivos adjuntos
  • Researchers at the Peripheral Neuropathies Lab. Universidad Miguel Hernández de Elche.
Regions: Europe, Spain, Belgium
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement